A

Ambit Biosciences

19 employees

Ambit Biosciences, a biopharmaceutical company, develops small molecule kinase inhibitors for cancer and inflammatory disease treatments.

Investor insights

Sectors invested in

Neurotoxicity1

Ediscovery1

Structure-efficacy relationships (SER)1

Health Care1

Medical1

In vitro preclinical efficacy1

In vivo preclinical efficacy1

CNS1

Funding rounds participated in

$1.5M sweet spot round size

Most of their 1 investments are in rounds between $1.5M and $1.5M

Basic info

Industry

biotechnology research

Sectors

Biotechnology

Health Care

Biopharma

Date founded

2000

Investments made

A

Afraxis, Inc raised $1.5M on September 19, 2008

Investors: Avalon Venture and Ambit Biosciences

Funding rounds raised

Total raised

$50M

from 25 investors over 25 rounds

A

Ambit Biosciences raised $50M on November 6, 2012

Investors: Gimv, Aisling Capital, OrbiMed Advisors, Radius Ventures, Apposite Capital and Forward Ventures

A

Ambit Biosciences raised $30M on June 10, 2011

Investors: Gimv, NovaQuest Capital Management, Apposite Capital, OrbiMed Advisors, Forward Ventures and Radius Ventures

A

Ambit Biosciences raised $49M on November 14, 2007

Investors: Gimv, OrbiMed Advisors, -, Forward Ventures, Radius Ventures, NovaQuest Capital Management and Horizon Technology Finance

A

Ambit Biosciences raised $31M on May 12, 2005

Investors: Gimv, -, Forward Ventures and Avalon Venture

A

Ambit Biosciences raised $19M on December 31, 2000

Investors: Forward Ventures and Avalon Venture